Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsBusiness Wire • Wednesday
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialBusiness Wire • 04/02/24
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical TrialBusiness Wire • 03/19/24
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialBusiness Wire • 03/01/24
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thBusiness Wire • 02/28/24
Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsBusiness Wire • 02/14/24
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerBusiness Wire • 01/29/24
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialBusiness Wire • 01/05/24
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 12/14/23
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer CenterBusiness Wire • 11/09/23
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial AgreementBusiness Wire • 10/23/23
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14Business Wire • 09/13/23
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung CancerBusiness Wire • 05/01/23
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung CancerBusiness Wire • 04/03/23
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology ResultsBusiness Wire • 02/28/23
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy ProposalsBusiness Wire • 02/23/23
SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial ProspectsPRNewsWire • 11/08/22
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development StrategyBusiness Wire • 10/06/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class ActionNewsfile Corp • 10/04/22